NCT01071252

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Conditions

• Chronic Plaque-type Psoriasis

Interventions

Type	Name	Description
DRUG	AIN457
DRUG	Placebo

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2010-02-19
• Last updated: 2015-02-16
• Results posted: 2015-02-16

Locations

19 sites across 6 countries: United States, Canada, Estonia, Iceland, Japan, Latvia